Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Tilia Fiduciary Partners Inc.

Tilia Fiduciary Partners Inc. trimmed its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 3.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 936 shares of the biotechnology company’s stock after selling 34 shares during the period. Tilia Fiduciary Partners Inc.’s holdings in Axon Enterprise were worth $374,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Avantax Advisory Services Inc. increased its holdings in Axon Enterprise by 0.8% in the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after purchasing an additional 40 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Axon Enterprise in the first quarter valued at about $931,000. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Axon Enterprise by 14.8% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock valued at $53,307,000 after buying an additional 22,013 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in Axon Enterprise by 21.7% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company’s stock worth $2,693,000 after acquiring an additional 1,634 shares in the last quarter. Finally, Zurich Insurance Group Ltd FI boosted its holdings in Axon Enterprise by 1.9% in the 2nd quarter. Zurich Insurance Group Ltd FI now owns 205,015 shares of the biotechnology company’s stock worth $60,324,000 after acquiring an additional 3,832 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Axon Enterprise

In other news, CEO Patrick W. Smith sold 4,767 shares of the stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $404.14, for a total value of $1,926,535.38. Following the completion of the transaction, the chief executive officer now owns 2,925,060 shares of the company’s stock, valued at approximately $1,182,133,748.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CEO Patrick W. Smith sold 4,767 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $404.14, for a total value of $1,926,535.38. Following the completion of the sale, the chief executive officer now directly owns 2,925,060 shares of the company’s stock, valued at approximately $1,182,133,748.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Julie A. Cullivan sold 900 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $353.53, for a total transaction of $318,177.00. Following the transaction, the director now owns 3,653 shares in the company, valued at $1,291,445.09. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 370,172 shares of company stock worth $136,562,182 in the last three months. 6.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Craig Hallum boosted their target price on shares of Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Jefferies Financial Group started coverage on Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price for the company. Northland Securities lifted their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Barclays upped their target price on Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Finally, Robert W. Baird upped their price target on shares of Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus target price of $365.38.

Axon Enterprise Stock Performance

Shares of AXON traded up $2.08 during midday trading on Wednesday, hitting $429.07. 61,610 shares of the stock traded hands, compared to its average volume of 524,160. The business’s 50 day moving average price is $370.34 and its two-hundred day moving average price is $325.13. The firm has a market capitalization of $32.42 billion, a PE ratio of 124.85, a price-to-earnings-growth ratio of 11.30 and a beta of 0.94. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. Axon Enterprise, Inc. has a 1-year low of $199.29 and a 1-year high of $433.48.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The firm had revenue of $504.00 million during the quarter, compared to analyst estimates of $478.35 million. During the same period in the previous year, the business posted $0.80 EPS. Axon Enterprise’s revenue was up 34.5% on a year-over-year basis. Equities research analysts predict that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.